Search Within

Lisa Bodei

  1. "Center for Pancreatic Cancer Research"
Formats
  1. Journal Article (11)
  2. Book Section (8)
  3. Meeting Abstract (8)
  4. Review (4)
  5. Editorial (2)
  6. Book Whole (1)
  7. Correspondence (1)
Groups
  1. Center for Pancreatic Cancer Research (35)
  2. Molecular Imaging and Therapy Service (35)
  3. Radiology, Department of (35)
  4. Sloan Kettering Institute Postdocs (35)
  5. Department of Medicine (22)
  6. Solid Tumor Oncology Division (22)

More Groups

People
  1. Jason Lewis (18)
  2. Diane Reidy (17)
  3. Heiko Schoder (10)
  4. Nitya Raj (9)
  5. Simone Krebs (8)
  6. Joseph O'Donoghue (6)

More People

Years
  1. 2024 (4)
  2. 2023 (12)
  3. 2022 (5)
  4. 2021 (3)
  5. 2020 (4)
  6. 2019 (2)

More Years

Publications
  1. Radiopharmaceutical Therapy (9)
  2. Journal of Nuclear Medicine (8)
  3. European Journal of Nuclear Medicine and Molecular Imaging (4)
  4. Pancreas (3)
  5. Journal of Clinical Oncology (2)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. Springer (13)
  2. Society of Nuclear Medicine (8)
  3. Lippincott Williams & Wilkins (4)
  4. American Society of Clinical Oncology (2)
  5. Nature Publishing Group (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (35)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer
    Journal Article

    Korsen, J. A.; Gutierrez, J. A.; Tully, K. M.; Carter, L. M.; Samuels, Z. V.; Khitrov, S.; Poirier, J. T.; Rudin, C. M.; Chen, Y.; Morris, M. J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2022)

    Fulltext@MSK | Save
  • Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, R. K. G.; Krebs, S.; Reidy, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schoder, H.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
    Journal Article

    Kalidindi, T. M.; Lee, S. G.; Jou, K.; Chakraborty, G.; Skafida, M.; Tagawa, S. T.; Bander, N. H.; Schoder, H.; Bodei, L.; Pandit-Taskar, N.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE
    Meeting Abstract

    Coffman, K. L.; Bodei, L.; Le, T.; Choi, Y.; Chou, J. F.; Capanu, M.; Dunphy, M.; Fox, J. J.; Grewal, R. K.; Reddy, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The future of nuclear medicine, molecular imaging, and theranostics
    Editorial

    Weber, W. A.; Czernin, J.; Anderson, C. J.; Badawi, R. D.; Barthel, H.; Bengel, F.; Bodei, L.; Buvat, I.; DiCarli, M.; Graham, M. M.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Journal Article

    Krebs, S.; O'Donoghue, J. A.; Biegel, E.; Beattie, B. J.; Reidy, D.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
    European Journal of Nuclear Medicine and Molecular Imaging (2020)

    Fulltext@MSK | Save
  • Peptide receptor radionuclide therapy during the COVID-19 pandemic: Are there any concerns?
    Correspondence

    Bodei, L.; Bergsland, E.; de Herder, W. W.; Ferone, D.; Hicks, R. J.; Hope, T. A.; Kunikowska, J.; Pavel, M.; Reidy-Lagunes, D.; Siveke, J.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy
    Review

    Hope, T. A.; Bodei, L.; Chan, J. A.; El-Haddad, G.; Fidelman, N.; Kunz, P. L.; Mailman, J.; Menda, Y.; Metz, D. C.; Mittra, E. S.; more...
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-satoreotide tetraxetan
    Journal Article

    Reidy-Lagunes, D.; Pandit-Taskar, N.; O'Donoghue, J. A.; Krebs, S.; Staton, K. D.; Lyashchenko, S. K.; Lewis, J. S.; Raj, N.; Gönen, M.; Lohrmann, C.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Biodistribution and radiation dose estimates for (68)Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors
    Journal Article

    Krebs, S.; Pandit-Taskar, N.; Reidy, D.; Beattie, B. J.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; O'Donoghue, J. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save